Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
2.105
+0.095 (4.73%)
At close: Feb 21, 2025, 4:00 PM
2.200
+0.095 (4.51%)
After-hours: Feb 21, 2025, 5:59 PM EST
Armata Pharmaceuticals Revenue
Armata Pharmaceuticals had revenue of $2.97M in the quarter ending September 30, 2024, with 142.69% growth. This brings the company's revenue in the last twelve months to $5.47M, up 34.92% year-over-year. In the year 2023, Armata Pharmaceuticals had annual revenue of $4.53M, down -17.77%.
Revenue (ttm)
$5.47M
Revenue Growth
+34.92%
P/S Ratio
13.92
Revenue / Employee
$82,833
Employees
66
Market Cap
76.17M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ARMP News
- 2 months ago - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Structural Biology Publication - PRNewsWire
- 6 months ago - Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - PRNewsWire
- 6 months ago - Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - PRNewsWire